Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pelthos Launches Zelsuvmi for At-Home Molluscum Contagiosum Treatment
Details : Zelsuvmi (berdazimer sodium) is a nitric oxide releasing agent indicated for the topical treatment of molluscum contagiosum in adults and pediatric patients 1 year of age and older.
Product Name : Zelsuvmi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 10, 2025
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Channel Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Pelthos Therapeutics Completes Merger with Channel Therapeutics
Details : The combined company plans to launch Zelsuvmi (berdazimer) topical gel, a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum.
Product Name : Zelsuvmi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 02, 2025
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Channel Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Murchinson
Deal Size : $50.1 million
Deal Type : Private Placement
Pelthos Therapeutics Closes $50.1 Million Private Placement
Details : Pelthos will initially focus on the launch and commercialization of Zelsuvmi (berdazimer) topical gel, a nitric oxide releasing agent indicated for the topical treatment of molluscum contagiosum.
Product Name : Zelsuvmi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 02, 2025
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Murchinson
Deal Size : $50.1 million
Deal Type : Private Placement
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : CHRO Merger
Deal Size : Undisclosed
Deal Type : Merger
Ligand's Pelthos unit merges with Channel to launch Zelsuvmi
Details : The combined company will initially focus on accelerating the commercialization of Pelthos’ Zelsuvmi (berdazimer sodium) topical gel for the treatment of Molluscum contagiosum infections.
Product Name : Zelsuvmi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 17, 2025
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : CHRO Merger
Deal Size : Undisclosed
Deal Type : Merger